Related Experiment Video
Updated: May 28, 2026
09:58
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
Published on: April 13, 2010
Eosinophilic activity and bronchial hyperresponsiveness within an asthmatic paediatric population
A Boumendjel1, A Tridon, M Messarah
1Applied Biochemistry and Microbiology Laboratory, Faculty of Sciences, University of Badji Mokhtar, BP12, SidiAmar, 23000, Annaba, Algeria.
Allergologia Et Immunopathologia
|October 4, 2011
Summary
Serum eosinophil cationic protein (ECP) is a valuable, non-invasive marker for assessing asthma severity and bronchial hyperresponsiveness in children. Elevated ECP levels correlate with increased asthma sensitivity and severity.
Area of Science:
- Pediatric Pulmonology
- Clinical Immunology
- Biomarker Discovery
Background:
- Asthma in children presents diagnostic challenges.
- Non-invasive markers are needed for objective assessment.
- Bronchial hyperresponsiveness (BHR) is a key asthma feature.
Purpose of the Study:
- To evaluate serum eosinophil cationic protein (ECP) as a non-invasive marker for BHR in pediatric asthma.
- To determine if ECP can predict asthma severity and sensitivities.
- To compare ECP with eosinophilia and IgE levels.
Main Methods:
- Study included 75 pediatric asthma patients (average age 9 years).
- Data collected via clinical questionnaires and biological tests.
- Assessed serum ECP, eosinophilia, and total IgE levels.
Main Results:
- Serum ECP levels significantly correlated with asthma severity (p<0.05).
- ECP demonstrated a stronger association with asthma severity and sensitivities (r=0.65) than eosinophilia.
- ECP proved to be a relevant clinical-biological marker.
Conclusions:
- Serum ECP levels are a reliable biological marker for pediatric asthma.
- ECP evaluation aids in objectively assessing asthma severity and sensitivities.
- ECP offers a non-invasive approach to asthma management.
Related Concept Videos
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
01:29Asthma-I: Introduction
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...